A Phase III Study of Ceralasertib plus Durvalumab versus Docetaxel in Patients with Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy - LATIFY

Exclusion Criteria

• - Participant with mixed SCLC and NSCLC histology.
• - History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention.
• - Persistent toxicities (CTCAE Grade > 2) caused by previous anticancer therapy.
• - Active or prior documented autoimmune or inflammatory disorders.
• - Participants who have received more than one line of prior anti-PD-(L)1, either alone or in any combination.
• - Participants:
• (a) Must not have experienced a toxicity that led to permanent discontinuation of the prior anti-PD(L)1 therapy.
• (b) All AEs while receiving prior anti-PD(L)1 therapy must have completely resolved.
• (c) Must not have experienced a Grade ≥ 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy.
• (d) Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
• - Participants who have received more than one prior line of platinum-based chemotherapy in metastatic setting.
• - Participants who have received a prior ataxia telangiectasia and Rad3-related protein (ATR) inhibitor.